Jason Keyes
Keine laufenden Positionen mehr
Vermögen: 315 622 $ am 31.03.2024
Profil
Jason A.
Keyes served as the Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013.
He then worked as the Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018.
Following that, he became the Chief Financial Officer at Equillium, Inc. in 2018, a position he held until 2024.
In 2020, he also served as an Independent Director at Sesen Bio, Inc. .
Mr. Keyes obtained his undergraduate and graduate degrees from Stanford University.
He also holds an MBA from the University of California, Los Angeles, and another MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EQUILLIUM, INC.
0,39% | 02.01.2024 | 136 633 ( 0,39% ) | 315 622 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Jason Keyes
| Unternehmen | Position | Ende |
|---|---|---|
| EQUILLIUM, INC. | Director of Finance/CFO | 06.03.2024 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07.03.2023 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 23.02.2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Director of Finance/CFO | 01.01.2013 |
Ausbildung von Jason Keyes
| Stanford University | Graduate Degree |
| University of California, Los Angeles | Masters Business Admin |
| UCLA Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EQUILLIUM, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
